ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM, El Hassan AM, 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3 :87–98.
-
2
Lawn SD, Wilkinson RJ, 2006. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 28 :625–633.
-
3
Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, Trovati S, Parravicini C, Corbellino M, Meroni L, 2007. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 157 :1032–1036.
-
4
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 :1739–1746.
-
5
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38 :1266–1272.
-
6
TDR 2007. Eighteenth Programme Report/Progress 2005–2006. Available at: www.who.int/tdr. Accessed September 27, 2007.
-
7
Sindermann H, Engel KR, Fischer C, Bommer W for the Miltefosine Compassionate Use Program, 2004. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39 :1520–1523.
-
8
Schraner C, Hasse B, Hasse U, Bauman D, Faeh A, Burg G, Grimm F, Mathis A, Weber R, Günthard HF, 2005. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 40 :e120–e124.
-
9
Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE, 2006. Successful treatment of post-kala-azar-dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect 53 :e25–e27.
-
10
Dejenie Belay A, Asafa Y, Mesure J, Davidson RN, 2006. Successful miltefosine treatment of post-kala-azar-dermal leishmaniasis occurring during antiretroviral treatment. Ann Trop Med Parasitol 100 :223–227.
-
11
Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V, 2006. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 100 :698–700.
-
12
Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, Lazzarin A, Uberti-Foppa C, Cinque P, 2003. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 41 :5080–5084.
-
13
Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33 :57–61.
-
14
Pérez-Victoria FJ, Sánchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F, 2006. Mechanism of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 9 :26–39.
-
15
Berman J, Bryceson ADM, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA, 2006. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg 100S :S41–S44.
-
16
Sindermann H, Engel J, 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100S :S17–S20.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 238 | 185 | 8 |
| Full Text Views | 216 | 5 | 0 |
| PDF Downloads | 46 | 4 | 0 |
Post-Kala-Azar Dermal Leishmaniasis in an HIV-1–Infected Woman: Recovery after Amphotericin B Following Failure of Oral Miltefosine
Monica Guffanti
Monica Guffanti
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Monica Guffanti in
Current site
Google Scholar
PubMed
Search for other papers by Monica Guffanti in
Current site
Google Scholar
PubMed
Giovanni Gaiera
Giovanni Gaiera
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Giovanni Gaiera in
Current site
Google Scholar
PubMed
Search for other papers by Giovanni Gaiera in
Current site
Google Scholar
PubMed
Simona Bossolasco
Simona Bossolasco
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Simona Bossolasco in
Current site
Google Scholar
PubMed
Search for other papers by Simona Bossolasco in
Current site
Google Scholar
PubMed
Norberto Ceserani
Norberto Ceserani
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Norberto Ceserani in
Current site
Google Scholar
PubMed
Search for other papers by Norberto Ceserani in
Current site
Google Scholar
PubMed
Deborah Ratti
Deborah Ratti
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Deborah Ratti in
Current site
Google Scholar
PubMed
Search for other papers by Deborah Ratti in
Current site
Google Scholar
PubMed
Paola Cinque
Paola Cinque
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Paola Cinque in
Current site
Google Scholar
PubMed
Search for other papers by Paola Cinque in
Current site
Google Scholar
PubMed
Flavia Salmaso
Flavia Salmaso
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Flavia Salmaso in
Current site
Google Scholar
PubMed
Search for other papers by Flavia Salmaso in
Current site
Google Scholar
PubMed
Nicola Gianotti
Nicola Gianotti
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Nicola Gianotti in
Current site
Google Scholar
PubMed
Search for other papers by Nicola Gianotti in
Current site
Google Scholar
PubMed
Adriano Lazzarin
Adriano Lazzarin
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; STD Centre-Institute of Dermatological Sciences, IRCCS Ospedale Maggiore, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Adriano Lazzarin in
Current site
Google Scholar
PubMed
Search for other papers by Adriano Lazzarin in
Current site
Google Scholar
PubMed
We describe a case of post-kala-azar dermal leishmaniasis occurring after diagnosis of visceral leishmaniasis in an HIV-1–infected woman. The skin lesions did not recover after treatment with oral miltefosine at 100 mg/day for five cycles of 28 days but responded to treatment with liposomal amphotericin B.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM, El Hassan AM, 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3 :87–98.
-
2
Lawn SD, Wilkinson RJ, 2006. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 28 :625–633.
-
3
Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, Trovati S, Parravicini C, Corbellino M, Meroni L, 2007. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 157 :1032–1036.
-
4
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 :1739–1746.
-
5
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38 :1266–1272.
-
6
TDR 2007. Eighteenth Programme Report/Progress 2005–2006. Available at: www.who.int/tdr. Accessed September 27, 2007.
-
7
Sindermann H, Engel KR, Fischer C, Bommer W for the Miltefosine Compassionate Use Program, 2004. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39 :1520–1523.
-
8
Schraner C, Hasse B, Hasse U, Bauman D, Faeh A, Burg G, Grimm F, Mathis A, Weber R, Günthard HF, 2005. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 40 :e120–e124.
-
9
Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE, 2006. Successful treatment of post-kala-azar-dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect 53 :e25–e27.
-
10
Dejenie Belay A, Asafa Y, Mesure J, Davidson RN, 2006. Successful miltefosine treatment of post-kala-azar-dermal leishmaniasis occurring during antiretroviral treatment. Ann Trop Med Parasitol 100 :223–227.
-
11
Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V, 2006. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 100 :698–700.
-
12
Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, Lazzarin A, Uberti-Foppa C, Cinque P, 2003. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 41 :5080–5084.
-
13
Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33 :57–61.
-
14
Pérez-Victoria FJ, Sánchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F, 2006. Mechanism of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 9 :26–39.
-
15
Berman J, Bryceson ADM, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA, 2006. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg 100S :S41–S44.
-
16
Sindermann H, Engel J, 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100S :S17–S20.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 238 | 185 | 8 |
| Full Text Views | 216 | 5 | 0 |
| PDF Downloads | 46 | 4 | 0 |